A detailed history of Black Rock Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Black Rock Inc. holds 5,758,112 shares of PTGX stock, worth $226 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,758,112
Previous 5,569,485 3.39%
Holding current value
$226 Million
Previous $161 Million 23.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.66 - $34.8 $4.65 Million - $6.56 Million
188,627 Added 3.39%
5,758,112 $200 Million
Q1 2024

May 10, 2024

BUY
$21.79 - $32.15 $557,453 - $822,493
25,583 Added 0.46%
5,569,485 $161 Million
Q4 2023

Feb 13, 2024

BUY
$14.05 - $23.44 $4.42 Million - $7.37 Million
314,477 Added 6.01%
5,543,902 $127 Million
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $3.67 Million - $5.21 Million
220,152 Added 4.39%
5,229,425 $87.2 Million
Q2 2023

Aug 11, 2023

BUY
$18.02 - $29.36 $10.9 Million - $17.8 Million
607,056 Added 13.79%
5,009,273 $138 Million
Q1 2023

May 12, 2023

BUY
$10.78 - $25.38 $8.09 Million - $19 Million
750,060 Added 20.54%
4,402,217 $101 Million
Q4 2022

Feb 13, 2023

BUY
$7.36 - $11.17 $1.4 Million - $2.12 Million
189,773 Added 5.48%
3,652,157 $39.8 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $58,698 - $87,450
7,468 Added 0.22%
3,462,384 $29.2 Million
Q2 2022

Aug 12, 2022

BUY
$7.06 - $25.52 $1.47 Million - $5.33 Million
208,742 Added 6.43%
3,454,916 $27.3 Million
Q1 2022

May 12, 2022

SELL
$23.34 - $36.08 $827,683 - $1.28 Million
-35,462 Reduced 1.08%
3,246,174 $76.9 Million
Q4 2021

Feb 10, 2022

BUY
$17.63 - $37.1 $1.45 Million - $3.05 Million
82,140 Added 2.57%
3,281,636 $112 Million
Q3 2021

Nov 09, 2021

BUY
$12.95 - $49.69 $2.06 Million - $7.9 Million
158,955 Added 5.23%
3,199,496 $56.7 Million
Q2 2021

Aug 11, 2021

BUY
$25.57 - $44.88 $77.7 Million - $136 Million
3,040,541 New
3,040,541 $136 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.